Consumer Advertising and Compounded Medications
The increasing prevalence of direct-to-consumer (DTC) advertising that creates demand for ancillary or “off-label” uses of medications makes PCAB accreditation a crucial factor in upholding the integrity of compounding practices.
A striking example of the need for responsible oversight in compounding is the off-label prescribing and compounding of GLP-1 receptor agonists, such as semaglutide (e.g., Ozempic, Wegovy). Originally approved for diabetes and heart disease, these drugs quickly gained popularity for their weight loss benefits.
A well-known telehealth platform ran an ad during the championship football game earlier this year for these medications as a weight loss solution, triggering an unprecedented surge in online traffic and consumer interest.
The company’s stock value rose over 200% in a month due to its compounded semaglutide offerings, but shortly after that, the FDA removed semaglutide from the official drug shortage database. The FDA named April 22, 2025, as the date beyond which these drugs could no longer be legally compounded. This highlights the complex regulatory landscape surrounding compounded medications and the potential public health risks associated with their uncontrolled distribution.
The FDA has received many reports of adverse events related to compounded GLP-1 drugs, particularly when incorrect dosages or formulation inconsistencies were present.
Why PCAB Accreditation is More Important Than Ever
The Pharmacy Compounding Accreditation Board (PCAB), a service of ACHC, has long represented the benchmark of quality for compounders. PCAB Accreditation serves as a critical safeguard, ensuring that compounded medications meet stringent quality and consistency standards. PCAB-accredited pharmacies must adhere to:
- Comprehensive quality control measures to maintain consistency in compounded formulations.
- Contamination prevention protocols for both sterile and non-sterile compounding, and sterility for sterile compounding.
- Proper training and oversight to ensure pharmacists and technicians follow best practices.
Furthermore, PCAB accreditation of 503A pharmacies supports patient safety by ensuring that compounded medications are dispensed responsibly – ideally within the context of an established patient-physician relationship.
By undergoing rigorous evaluation and oversight, PCAB-accredited pharmacies show their commitment to the highest standards in sterile and non-sterile compounding.
Future of Compounded Medications: Balancing Innovation with Safety
The compounding industry is at an inflection point. Personalized medicine represents a pharmaceutical advancement and drug shortages are driving demand for compounding existing formulations. Ensuring the quality, safety and integrity of compounded drugs must remain a top priority.
PCAB accreditation provides pharmacies with the framework needed to meet these challenges while reinforcing public trust in compounded medications. As healthcare evolves, patients and providers alike must recognize the importance of seeking out accredited pharmacies to ensure that compounded medications are safe, effective, and consistently produced.
With the growing popularity of DTC advertising—particularly in weight loss and specialty treatments—ensuring responsible oversight has never been more essential. PCAB accreditation is the gold standard for compounding pharmacies, helping to protect patients and support the integrity of the industry.
—
Read more articles about PCAB Accreditation here.